Student and Faculty Publications
Publication Date
7-23-2024
Journal
Nature Communications
Abstract
Immunization programs against SARS-CoV-2 with commercial intramuscular vaccines prevent disease but are less efficient in preventing infections. Mucosal vaccines can provide improved protection against transmission, ideally for different variants of concern (VOCs) and related sarbecoviruses. Here, we report a multi-antigen, intranasal vaccine, NanoSTING-SN (NanoSTING-Spike-Nucleocapsid), eliminates virus replication in both the lungs and the nostrils upon challenge with the pathogenic SARS-CoV-2 Delta VOC. We further demonstrate that NanoSTING-SN prevents transmission of the SARS-CoV-2 Omicron VOC (BA.5) to vaccine-naïve hamsters. To evaluate protection against other sarbecoviruses, we immunized mice with NanoSTING-SN. We showed that immunization affords protection against SARS-CoV, leading to protection from weight loss and 100% survival in mice. In non-human primates, animals immunized with NanoSTING-SN show durable serum IgG responses (6 months) and nasal wash IgA responses cross-reactive to SARS-CoV-2 (XBB1.5), SARS-CoV and MERS-CoV antigens. These observations have two implications: (1) mucosal multi-antigen vaccines present a pathway to reducing transmission of respiratory viruses, and (2) eliciting immunity against multiple antigens can be advantageous in engineering pan-sarbecovirus vaccines.
Keywords
Animals, Administration, Intranasal, SARS-CoV-2, COVID-19, Mice, Cricetinae, Antibodies, Viral, COVID-19 Vaccines, Female, Mice, Inbred BALB C, Humans, Mesocricetus, Antigens, Viral, Spike Glycoprotein, Coronavirus, Immunoglobulin G, Antibodies, Neutralizing
Included in
Animals Commons, Bioinformatics Commons, Biomedical Informatics Commons, Influenza Virus Vaccines Commons, Medical Sciences Commons, Oncology Commons
Comments
Associated Data
PMID: 39043645